So far, patient enrollment for DIAGNODE-2 has exceeded our expectations.
More than 400 million people worldwide suffer from diabetes. 10-20% have an autoimmune form of the disease where the immune system attacks and destroys the insulin-producing beta cells. Autoimmune diabetes is a chronic disease and there is currently no cure.
Diamyd Medical develops the diabetes vaccine Diamyd®, based on the exclusively licensed GAD molecule. The Company’s licensed technologies GABA and Gliadin also have the potential to become key pieces of the puzzle to prevent, treat or cure autoimmune diabetes.
The development of Diamyd Medical’s licensed technologies for GAD, GABA and Gliadin, in combination or with other substances with various mechanisms of action, is carried out in clinical trials and preclinical studies. Six clinical trials are currently ongoing.